Inventor · disambiguated record
Tony Ho
Also filed as: HO TONY · HO TONY W · HO TONY WEI-HSIU
8 granted patents·12 pending applications·43 citations·filing 2001–2024
82Inventor score
Top patents by PatentIndex Score
20 records- 0187US6812248B2Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymesUNIV JOHNS HOPKINS·Filed 2001·Granted Nov 2, 2004·35 cites·6 claims
- 0284US11389481B2Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19CRISPR THERAPEUTICS AG·Filed 2021·Granted Jul 19, 2022·1 cites·20 claims
- 0382US8486696B2Cell populations which co-express CD49c and CD90HO TONY W·Filed 2005·Granted Jul 16, 2013·7 cites·68 claims
- 0472US2025041349A1CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses ThereofVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 0568US2022332828A1Anti-pd-l1 antibody treatment of bladder cancerMEDIMMUNE LLC·Filed 2022·Application pending·0 cites
- 0658US12161674B2CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereofVERTEX PHARMA·Filed 2018·Granted Dec 10, 2024·0 cites·16 claims
- 0758US10351826B2Cell populations which co-express CD49c and CD90HO TONY W·Filed 2007·Granted Jul 16, 2019·0 cites·4 claims
- 0856US2014073046A1Cell Populations Which Co-Express CD49C and CD90GARNET BIOTHERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 0956US2007231309A1Cell populations which co-express CD49c and CD90NEURONYX INC·Filed 2007·Application pending·0 cites
- 1056US2022249558A1Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19CRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 1156US2007243609A1Cell populations which co-express CD49c and CD90HO TONY W·Filed 2007·Application pending·0 cites
- 1255US2019359715A1Anti-pd-l1 antibody treatment of bladder cancerMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 1354US2022056438A1Gene-editing compositions and methods to modulate faah for treatment of neurological disordersCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1454US2022118019A1Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19CRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1550US9969977B2Cell populations which co-express CD49c and CD90HO TONY W·Filed 2002·Granted May 15, 2018·0 cites·16 claims
- 1648US9969980B2Cell populations which co-express CD49c and CD90HO TONY W·Filed 2001·Granted May 15, 2018·0 cites·5 claims
- 1748US9475773B2NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)ASTRAZENECA AB·Filed 2014·Granted Oct 25, 2016·0 cites·1 claims
- 1848US2007224177A1Cell populations which co-express CD49c and CD90HO TONY W·Filed 2007·Application pending·0 cites
- 1936US2008139614A1Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 AntagonistsSEABROOK GUY R·Filed 2005·Application pending·0 cites
- 2034US2017157109A1Nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)ASTRAZENECA AB·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tony Ho files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →